Our team of scientists, physicians, and technicians is committed to pushing the boundaries of drug discovery and development for a broad spectrum of neuropsychiatric conditions. We are advancing ground breaking technologies to reduce the serious side effects of ADHD medications and to create highly effective next-generation treatments for ADHD and other neuropsychiatric conditions. With over 30 years of experience in the pharmaceutical industry and more than 30 FDA approvals, our leadership team ensures the timely delivery of top-notch, innovative solutions in neuropsychiatry.
ADHD stands out as one of the most prevalent cognitive disabilities affecting both children and adults, with over 3 million cases receiving treatment annually, marking a 42% increase over the past decade.Stimulant compounds such as methylphenidate and amphetamine are the primary treatments prescribed for ADHD. However, these psycho stimulants come with a range of side effects. At Avekshan, we are dedicated to providing alternatives to these classic stimulant medications, benefiting patients, families, and physicians alike.
Stimulant Medication
The medications currently available for treating ADHD come with several potential side effects. These can include insomnia, appetite suppression, mood fluctuations, and changes in blood pressure. Psycho stimulants such as methylphenidate and amphetamine, the predominant ADHD treatment option, pose additional risks of abuse, misuse, and addiction.
Medication Adherence
It is estimated that nearly 50% of ADHD patients prescribed stimulant medications do not adhere to the prescription regimen.
Untreated ADHD
Not treating ADHD properly can have far-reaching consequences across academic, social, emotional, and personal domains. Untreated ADHD is associated with an elevated risk of nicotine and other substance use disorders and may also increase the likelihood of developing conduct disorders, including engagement in criminal behaviors.
Our team of expert scientists, physicians and technicians is actively pursuing novel ways to address the serious side effects of current ADHD medications and discovering and developing safe and highly efficacious new medications.
We take pride in our unique approach to creating viable and effective products ready for the market in response to current and future needs and industry standards.
Scientists and physicians from prestigious academic centers and a support team of experienced professionals ensure the highest scientific and clinical standards of safety and efficacy.
We are developing Norbinal as a potential candidate medication for sustained and consistent therapeutic effects, improved outcomes, and patient satisfaction in a broad spectrum of neuropsychiatric conditions including ADHD, Major Depressive Disorder and Fragile X syndrome.
Learn MoreAvekshan is developing AVK 001, a Fixed Dose Combination (FDC) of methylphenidate [MPH]hydrochloride and naltrexone [NTX] hydrochloride for the treatment of ADHD.
MPH (the same active ingredient in Ritalin®, Concerta® among others) is a central nervous system (CNS) stimulant indicated as an integral part of a total treatment program (typically including other psychological, educational, and social remedial measures) for a stabilizing effect in children and adults with attention deficit hyperactivity disorder(ADHD).
